A Phase 1/2A Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy

Inclusion Criteria

INCLUSION CRITERIA:

- Age: >/= 18 and
- Diagnosis:

- Histologically confirmed recurrent, locally advanced unresectable or metastatic
adenocarcinoma of the pancreas who have progressed after front line
chemotherapy, OR

- Histologically confirmed metastatic colorectal adenocarcinoma who have
progressed after at least 2 standard chemotherapy regimens.

- Tumor sections must stain >/= 20% positive for NPC-1C antibody/antigen target

- Measurable disease (by RECIST)

- Karnofsky performance status of >/= 50%

- Laboratory Function (within 21 days of receiving first dose of study drug):

- Hemoglobin > 8.5 g/dL, or on stable doses (hematocrit stable within 1 gram and
dose stable for one month) of erythropoietin or similar medication.

- Absolute neutrophil count (ANC) >/= 1,500/mm3

- Platelets >/= 50,000/mm3

- Total bilirubin
- ALT and AST 5 times the ULN

- Creatinine
- Voluntary written informed consent before performance of any study-related procedure
that is not part of normal medical care.

- Expected to be able to remain on a study protocol for at least 8 weeks.

- Is post-menopausal, surgically sterilized, or willing to use acceptable methods of
birth control for the duration of the study. Male subject agrees to use an
acceptable barrier method for contraception during the study.

EXCLUSION CRITERIA:

- Has history of disseminated or uncontrolled brain metastases or central nervous
system disease.

- Ascites with abdominal distention.

- Mechanical, non-reversible reason for not being able to eat, or have a likelihood of
developing malignant bowel obstruction during the course of the induction phase of
treatment; subjects with uncomplicated J-tubes will not be excluded.

- Any major surgery within four weeks of enrollment.

- Uncontrolled concomitant illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
arrhythmia.

- Has another serious medical illness, including a second malignancy, or psychiatric
illness that could, in the Investigator's opinion, potentially interfere with the
completion of treatment according to this protocol.

- Pregnant or breast-feeding.

- Any chemotherapeutic agents or corticosteroids within 2 weeks of study entry or
biologic treatment within 4 weeks of study entry.

- Use of any high risk medications that prolong the QT/QTc interval.

- History of allergic reaction to Erbitux greater than grade 1.

- Uncontrolled diabetes.

- Prior history of a documented hemolytic event.

- Receiving warfarin.